Lisa Wolf's departure as Chief Operating Officer and Chief Financial Officer of Valion Bio, Inc. was reported; the filing names no successor. As of November 6, 2026, Valion Bio, Inc. has reported 6 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 4, 2026 to November 5, 2026, naming 5 appointments and 2 departures (Form 8-K, November 5, 2026).
Valion Bio, Inc. named a new Chief Executive Officer on Sep 23. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Valion Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Lisa Wolf · Role: Chief Operating Officer and Chief Financial Officer · 8-K, 2026-11-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-02
- · In / out: In · Person: Dean Zikria · Role: Chief Executive Officer · 8-K, 2026-09-23
- · In / out: In · Person: Jared Malbin · Role: Director · 8-K, 2026-09-01
- · In / out: In · Person: Lisa Wolf · Role: Chief Operating Officer · 8-K, 2026-08-17
Valion Bio, Inc. reported changes in 6 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-04 to 2026-11-05. They name 6 people, with 5 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Valion Bio, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-11-14 (layoff filings and notices).
Also on the record for Valion Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 4, 2026 | Stake report, Schedule 13G/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| September 3, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| September 2, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 27, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13D/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13D, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by Murchinson Ltd. | 9.99% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
| February 27, 2026 | Stake report, Schedule 13G, by 3i, LP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Valion Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Valion Bio, Inc. and the records around it.
Valion Bio, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Company profile and every filing Dec 2025
- Form D filing Dec 2025
- Form D filing Dec 2025
- Layoff notices Nov 2025
- Who owns it
Companies that share a holder
- Murchinson Ltd. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Oct 2026), Pelthos Therapeutics Inc. (Nov 2025)
- 3i, LP also filed stake reports on 11 other companies: Netcapital Inc. (May 2026), Pelthos Therapeutics Inc. (May 2026), zSpace, Inc. (Apr 2026)
Watch Valion Bio, Inc.
Get an email when Valion Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Valion Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Valion Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Valion Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Out | Chief Operating Officer and Chief Financial Officer | 8-K, 2026-11-05 | ||
| 2026-11-02 | Reported | not named in the filing | 8-K, 2026-11-02 | ||
| 2026-09-23 | In | Chief Executive Officer | 8-K, 2026-09-23 | ||
| 2026-09-23 | Out | 8-K, 2026-09-23 | |||
| 2026-09-01 | In | Director | 8-K, 2026-09-01 | ||
| 2026-09-01 | In | Director | 8-K, 2026-09-01 | ||
| 2026-08-17 | In | Chief Operating Officer | 8-K, 2026-08-17 | ||
| 2026-05-04 | In | General Counsel | 8-K, 2026-05-04 |
Who leads Valion Bio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer and Chief Financial Officer: Lisa Wolf, departure reported (filed 2026-11-05). No successor is named in these filings.
- Chief Executive Officer: Dean Zikria, appointed (filed 2026-09-23).
- Director: Jared Malbin, appointed (filed 2026-09-01).
- Chief Operating Officer: Lisa Wolf, appointed (filed 2026-08-17).
- General Counsel: Melinda Lackey, appointed (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Valion Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Valion Bio, Inc. (free up to 3)
Find people with the same kind of experience as the Chief Operating Officer and Chief Financial Officer at Valion Bio, Inc., with the record behind each one.
Find candidates like Chief Operating Officer and Chief Financial Officer at Valion Bio, Inc.Every change, in the filing's words
Departing: Lisa Wolf, Chief Operating Officer and Chief Financial Officer
Item 5.02(b) On October 31, 2026, Lisa Wolf notified the Special Committee of the Board of Directors of Valion Bio, Inc. (the "Company") of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company.
- Ms. Wolf's resignation from each of these positions will become effective on December 11, 2026.
Reported
Item 5.02(b) On October 27, 2026, Valion Bio, Inc. (the "Company") notified Melinda Lackey, the Company's General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment, effective October 30, 2026.
- Under the Separation Agreement, subject to Ms. Lackey's compliance with its terms and the satisfaction of the conditions set forth therein, the Company agreed to pay Ms. Lackey a gross cash severance payment of $26,750, less applicable taxes and withholdings, in a single lump-sum payment no later than 30 days following the effective date of the Separation Agreement.
- In addition, if Ms. Lackey is eligible for and properly elects continued medical or dental coverage under COBRA, the Company agreed to pay the applicable COBRA premiums for Ms. Lackey and her covered dependents until the earlier of November 30, 2026 or the date on which she becomes eligible for healthcare coverage under a subsequent employer's health plan.
- The Separation Agreement also provides for a general release of claims by Ms. Lackey in favor of the Company and certain related parties and includes customary confidentiality, non-disparagement, cooperation, return-of-property and other continuing obligations.
- Ms. Lackey agreed to forfeit any unvested equity awards and may exercise any vested stock options only in accordance with the applicable equity plan documents.
Appointed: Dean Zikria, Chief Executive Officer
On September 22, 2026, Valion Bio, Inc. (the "Company"), a Delaware corporation, appointed Dean Zikria as Interim Chief Executive Officer of the Company, effective immediately.
Departing: Sheryle Bolton
Board Resignation On September 17, 2026, Sheryle Bolton notified the Company of her decision to resign from the Company's Board, effective immediately.
- Mr. Zikria remains a member of the Company's Board of Directors (the "Board").
- Mr. Zikria, 58, has served as a director on our Board since July 10, 2019.
- Mr. Zikria brings deep industry experience in allergy and asthma as well as other chronic diseases to the board.
- Since August 2019, Mr. Zikria has been the Founder, CEO and Chairman of Mind Machine LLC, a Silicon Valley based marketing/advertising agency - focused on the MedTech industry.
- From June 1, 2021, until January 2023, he served as the Chief Commercial Officer at Intuity Medical Inc., a Silicon Valley MedTech company launching a highly disruptive glucose meter in the diabetes industry.
- In addition, he has served as Chairman of DZ Advisors, LLC, a company founded by Mr. Zikria in 2017 that provides consulting and advisory services to the medtech, biotech, digital health and pharmaceutical industries; since inception, where he also served as President from December 2017 until May 31, 2021.
- Mr. Zikria also sits on the boards of the following privately held companies: AsthmaTek, Inc., a startup digital health company in the asthma space; Brev.Dev, Inc., a technology company developing a disruptive platform to aid developers.
- Mr. Zikria previously served as Chief Executive Officer of Spirosure Inc., a FeNO detection company for asthma diagnostics, from 2014 to 2017.
Appointed: Jared Malbin, Director
On August 27, 2026, the Company appointed Jared Malbin as a member of the board of directors (the "Board"), effective immediately.
Appointed: Thomas Jensen, Director
On August 27, 2026, the Company appointed Thomas Jensen as a member of the Board, effective immediately.
- Mr. Malbin, 47, has more than 25 years of experience in the financial services industry, spanning broker-dealer operations, compliance, finance and capital markets.
- Since 2024, Mr. Malbin has served as Chief Operating Officer of Lucid Capital Markets, LLC, a boutique investment banking broker-dealer, where he oversees firm operations and regulatory strategy across the firm's capital markets and trading businesses.
- Prior to that, from 2019 to 2024, Mr. Malbin served in senior executive and management roles at investment firms.
- He has extensive experience building regulatory and compliance functions and guiding firms through regulatory examinations and approval processes.
- Mr. Malbin also serves on the boards of two private insurance companies.
- Mr. Malbin holds a Bachelor of Arts degree from Tufts University.
- Mr. Jensen, 47, has more than 20 years of global biotechnology and oncology experience spanning research and development, corporate strategy and business leadership.
- Since December 2023, Mr. Jensen has served as Chief Executive Officer of Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity"), a clinical-stage pharmaceutical company, where he oversees the advancement of stenoparib, a dual PARP/WNT inhibitor, through Phase 2 trials in advanced ovarian cancer.
Appointed: Lisa Wolf, Chief Operating Officer
On August 16, 2026, Valion Bio, Inc. (the "Company"), a Delaware corporation, appointed Lisa Wolf as Chief Operating Officer of the Company, effective immediately.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Ms. Wolf remains as the Company's Chief Financial Officer.
- Ms. Wolf, 64, has served as the Company's Chief Financial Officer since July 3, 2025, prior to which she served as interim Chief Financial Officer from October 2024 until July 2025.
- Ms. Wolf brings over 30 years of experience in public accounting and private industry, including for both public and private companies spanning multiple industries.
- Ms. Wolf has played a key role in supporting the Company's accounting and SEC reporting functions on an out-sourced basis since June 2022, when she joined Murdock Martell as Vice President.
- Murdock Martell is a consulting and recruiting firm offering cutting-edge finance, accounting and human relations solutions focused primarily on life science and technology sectors.
- Prior to joining Murdock Martell, Ms. Wolf spent eight years at Resonant, Inc. (Nasdaq: RESN), a micro-cap public technology company that was acquired by Murata Electronics North America, Inc. in March 2022, initially serving as Vice President of Finance and then Chief Accounting Officer of Resonant, Inc. Ms. Wolf holds a B.S. in Business Administration from California State University, Northridge and earned her CPA while working at Arthur Andersen.
Appointed: Melinda Lackey, General Counsel
On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.), a Delaware corporation (the "Company").
- Ms. Lackey, age 49, brings over 18 years of legal and corporate experience, and has served in executive and legal leadership roles at biotechnology companies and international law firms.
- Prior to joining the Company, from November 2021 until August 2025, Ms. Lackey served as Senior Vice President, Legal & Administration of Alaunos Therapeutics, Inc. (NASDAQ: TCRT).
- From August 2021 to November 2021, she served as Of Counsel at Hogan Lovells.
- Prior to that, Ms. Lackey served as General Counsel of Kuur Therapeutics, Inc. (f/k/a Cell Medica, Inc.), was a clinical-stage biotechnology company focused on CAR-NKT cellular therapies and later acquired by a global biopharmaceutical public company, from June 2018 to August 2021.
- Ms. Lackey previously practiced law at Winston & Strawn LLP from March 2008 to June 2018, where she focused on intellectual property strategy and patent litigation.
- Ms. Lackey earned a Bachelor of Science in microbiology from Texas Tech University in 1998.
- Ms. Lackey also earned a Master of Science in medical microbiology and immunology from Texas Tech University Health Sciences Center and a Doctor of Jurisprudence from University of Houston Law Center in 2007.
Valion Bio, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Valion Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.